Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphoblastic Leukemia
Research reports from Food & Drug Administration provide new insights into acute lymphoblastic leukemia
March 23rd, 2008
According to recent research published in the journal Clinical Cancer Research, "On June 28, 2006, the U.S. Food and Drug Administration approved dasatinib (Sprycel; Bristol-Myers Squibb), a new small-molecule inhibitor of multiple tyrosine kinases, for the treatment of adults with chronic phase, accelerated phase, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy including imatinib." "This summary reviews the database supporting this approval. Four single-arm multicenter studies supported the efficacy and safety of dasatinib....
Source: Pharma Investments, Ventures & Law Weekly (2008-03-23)
|
